1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Application window was September 15 – November 21, 2025; deadline has passed.
"BioBoost Manufacturing Scale-Up Program" is currently closed and not accepting applications.
BioBoost Manufacturing Scale-Up Program is sponsored by Massachusetts Life Sciences Center (MLSC). Supports companies expanding biomanufacturing or medtech advanced manufacturing operations in Massachusetts.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
BioBoost Eligibility and Evaluation - MLSC BioBoost Eligibility and Evaluation The application period will run from Sept. 15 – Nov. 21, 2025 at 1 p.
m. EST. Massachusetts is a global leader in life science research and development.
The Commonwealth also has a strong growing manufacturing presence. Many of the world’s top biotech, pharma, and medtech companies have chosen to co-locate their R&D and manufacturing operations in Massachusetts to take advantage of the density of talent, collaborative spirit, and opportunities for consistent iteration between the lab and production teams.
These close collaborative connections work even better on the cutting-edge innovations when the manufacturing processes are nimble, creative, and responsive to the lightning speed of science. The MLSC’s BioBoost Manufacturing Scale-Up program supports companies creating or expanding their biomanufacturing or medtech advanced manufacturing presence in Massachusetts.
This program aims to be a responsive and adaptive tool to fund capital investments, such as buildout, renovation, or equipment needs in a way that best meets current and future industry needs to support increased manufacturing activity and career development in Massachusetts.
The BioBoost program will award funding of up to $3,000,000 per project in capital funding to support life science companies or partner nonprofits that can build or scale new manufacturing operations in Massachusetts.
Separately, the BioBoost program will award funding of up to $500,000 per project to support real estate developers’ site readiness study or other planning/evaluation needs to develop a particular target property for life science manufacturing use.
Funding will be given to projects that can demonstrate a broader public benefit and contribute to the larger life sciences ecosystem including workforce training space and programming, offering access or discounts to small local companies, or collaboration with nonprofit partners. The MLSC anticipates awarding up to three grants for direct manufacturing scale-up between $1,000,000 and $3,000,000 for two (2) years of work.
The MLSC anticipates awarding one to two grants for real estate developer evaluation between $250,000 and $500,000 for one (1) year of work. The “life sciences” are defined in the MLSC’s enabling legislation as “advanced and applied sciences that expand the understanding of human physiology and have the potential to lead to medical advances or therapeutic applications .
” This program is intended to help build life science manufacturing capacity within the Commonwealth. These funds will: Support the establishment or growth of manufacturing operations, whether through additional buildout, renovations, or equipment purchase Support the development of additional physical sites through funding site readiness studies or other evaluation by real estate developers The application period will run from Sept.
15, 2025 – Nov. 21, 2025. Company / nonprofit applicants must use funds to create or expand biomanufacturing or medtech advanced manufacturing operations within Massachusetts, such as funding buildout, renovation, or equipment needs.
Real estate developer applicants must use funds to conduct feasibility studies or otherwise assess specific site readiness for potential life science manufacturing purposes. Life Science Company of any size, based in Massachusetts or looking to expand to Massachusetts.
MA-based companies are required to submit a Certificate of Good Standing from the Massachusetts Secretary of State and a Certificate of Good Standing from the Massachusetts Department of Revenue. Non–MA companies must establish a Massachusetts presence before using funds.
Community-Based Organizations (CBOs), including CBOs relying on a fiscal agent Community Colleges, Colleges, and Universities Real Estate Developers / Firms Workforce Development Organizations Successful proposals will explain how the requested funds will create additional manufacturing capacity in Massachusetts, as well as describe how that capacity will support the continued growth of the life sciences workforce and the larger life sciences ecosystem.
Applications will only be accepted through the MLSC’s online application portal, accessed via: MLSC Application Manager . Applicants are required to create an account and complete a user profile before starting the application. It is recommended that applicants carefully follow the online instructions and provide complete, clear, and concise responses to all required questions.
It is the sole responsibility of the applicant to ensure that its application is complete, meets minimum threshold requirements and is properly submitted to MLSC prior to the established deadline. Multiple users can be given access to the application. Applicants are asked to review the MLSC’s Public Disclosure policy prior to submitting their application.
MLSC staff will conduct an initial administrative review to determine the eligibility of all submitted applications. Eligible applicants will then be reviewed and scored. Funding recommendations will then be made to the MLSC Board of Directors based on feedback and scores.
The amount and number of awards will be determined by the quality of the proposals. MLSC staff may contact the applicant to request supplemental information prior to formal review. In addition, MLSC reserves the right to make no awards, to award less than the applicant requests, and/or to award less than the maximum amount of funds potentially available through this solicitation.
Expected impact on an active business decision, with priority for new manufacturing locations | 30 Extent of public benefit / breadth of ecosystem stakeholders affected | 20 Potential impact on regional economic development | 5 Potential to create high-quality jobs in Massachusetts and a commitment to workforce training and development initiatives, especially by partnering with education or training organizations | 10 Expected capital expenditure (larger projects prioritized) | 5 Timeline (quicker projects prioritized) | 5 Budget accuracy and reasonableness | 15 Outcomes seem attainable | 10 Please note: The MLSC reserves the right to consider the applicant’s past performance in operating grants administered by both the Center and/or the Commonwealth and factor this performance into funding decisions.
All applicants will be notified of their award status by email. In addition to the scoring system outlined, the Center reserves the right to only consider submissions that, in our sole judgment, are complete and responsive to the solicitation’s requirements and include all required application components. Additionally, the Center reserves the right to consider other criteria in making awards.
Grant funds shall be used for activities including, but not limited to: Allowable costs for MLSC funds include: equipment, renovations, buildout, and purchase of hardware and software, research supplies and reagents. Following the execution of the grant agreement, funds will be provided on a reimbursement basis to the Awardees based on the terms of the Grant Agreement.
The number and amount of awards will be determined by the quality of the proposals. The Center reserves the right to adjust the requested amount of funding for each proposal.
Activities that are NOT eligible for funding include, but are not limited to: Direct labor, legal expenses, travel, paying off debt, paying board members, paying for operating costs such as rent and utilities, renting space for storage of memory or hard drives, monthly cloud storage fees, other monthly subscription fees, and activities funded by other funding sources.
Following execution of the Grant Agreement, funds will be provided via electronic fund transfer (EFT) on a reimbursement basis as the relevant receipts and reports have been received and upon verification of those costs. Budget must include an itemized list of equipment, materials, supplies, and/or technology with the estimated cost for each item.
If applicable, budget must be separated under fiscal year in which the expense will be incurred. FY26 and FY27 expenses. If you have any questions regarding the application process, e-mail: bioboost@masslifesciences.
com . Data Science Internship Program Accepting Applications , Internships High School Apprenticeship Challenge Novel Therapeutics Delivery COVID-19 Response , Manufacturing COVID-19 Manufacturing Emergency Response Team Funding Accelerating Coronavirus Testing Solutions (A. C.
T. S.) Join the Heart of the Hub This field is for validation purposes and should be left unchanged.
According to the current listing, eligibility includes: Life science companies of any size, based in Massachusetts or looking to expand to Massachusetts. Confirm the full requirements in the official notice before applying.
The current listing shows $1,000,000 - $3,000,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was November 21, 2025, which has passed. Check the official notice for any future application windows before investing time in a proposal.
BioBoost Manufacturing Scale-Up Program is funded by Massachusetts Life Sciences Center (MLSC). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Massachusetts. If your organization operates elsewhere, check the official notice for location requirements.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
The U.S. Government Policy for Stopping High-Risk Life Sciences Research, released July 28, 2026 under EO 14292 and implemented at NIH through NOT-OD-26-101, replaces mitigation with prohibition. It bans dangerous gain-of-function research outright, gates potential DGOF behind government-wide review, and creates International Research of Concern — a research-security regime wearing biosafety clothing. Penalties run to five-year debarment and False Claims Act exposure.
Read articleAwards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read article